
Companies that alerted European authorities to cartels in the last 16 years dodged 10 billion euros ($9.97 billion) in potential fines, EU antitrust regulators said on Tuesday as they announced efforts to encourage more whistleblowing.
Launched in 1996 and revised several times since then, the European Commission’s leniency programme offers the first company that reports wrongdoing total immunity from fines while those that subsequently come forward with evidence can get discounts up to 50%.
Related: Recent EU Developments in Buyer-Side Cartels
Businesses operating in the European Economic Area that have cooperated since 2006 have experienced fines decreasing by 16 billion euros, while immunity applicants have experienced a 10 billion euro decrease and reduction of fines applications have received a 6 billion euro decrease, the Commission said in a statement.
It said the total amount of fines imposed during the same period was 15 billion euros. The EEA includes the 27 EU countries, Iceland, Liechtenstein and Norway.
Making it even easier for whistleblowers to test the water before committing themselves to the procedure, the leniency programme allows companies to start informal talks with the EU competition enforcer without disclosing their names and the sector they are in.
They can also make a hypothetical application with details of wrongdoing to see if they qualify for reduced fines.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas